Legend Biotech (LEGN) Liabilities and Shareholders Equity (2019 - 2025)

Legend Biotech's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $1.7 billion for Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 3.8% year-over-year to $1.7 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.8 billion (down 3.25% YoY) and the FY2025 annual result came in at $1.7 billion, up 3.8% from the prior year.
• Liabilities and Shareholders Equity was $1.7 billion for Q4 2025 at Legend Biotech, up from $1.7 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $875.1 billion in Q2 2021 and bottomed at $813.8 million in Q3 2021.
• A 5-year average of $84.2 billion and a median of $1.7 billion in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Peak annual rise in Liabilities and Shareholders Equity reached 55.03% in 2021, while the deepest fall reached 99.89% in 2021.
• Legend Biotech's Liabilities and Shareholders Equity stood at $1.1 billion in 2021, then grew by 18.89% to $1.3 billion in 2022, then jumped by 38.89% to $1.8 billion in 2023, then slipped by 9.65% to $1.7 billion in 2024, then rose by 3.8% to $1.7 billion in 2025.
• Business Quant data shows LEGN's Liabilities and Shareholders Equity at $1.7 billion in Q4 2025, $1.7 billion in Q3 2025, and $1.7 billion in Q2 2025.